Steven Lichtman
Stock Analyst at William Blair
(2.73)
# 1,540
Out of 5,182 analysts
74
Total ratings
37.04%
Success rate
9.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENOV Enovis | Assumes: Outperform | n/a | $24.54 | - | 1 | Apr 17, 2026 | |
| MMED MiniMed Group | Initiates: Outperform | n/a | $12.92 | - | 1 | Mar 31, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $19.82 | +11.00% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $188.31 | +93.83% | 8 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $59.95 | +108.51% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $61.41 | +66.10% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $92.59 | +45.80% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $2.63 | +356.27% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $76.01 | +44.72% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $82.92 | +13.36% | 10 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $65 | $7.29 | +791.63% | 8 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $5.5 | $16.50 | -66.67% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $11.09 | +8.21% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $67.43 | +29.02% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 | $4.35 | +2,313.79% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $329.01 | -12.46% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $122.07 | -13.98% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $26.68 | +462.22% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $64.34 | +32.11% | 3 | Sep 4, 2020 |
Enovis
Apr 17, 2026
Assumes: Outperform
Price Target: n/a
Current: $24.54
Upside: -
MiniMed Group
Mar 31, 2026
Initiates: Outperform
Price Target: n/a
Current: $12.92
Upside: -
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $19.82
Upside: +11.00%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $188.31
Upside: +93.83%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $59.95
Upside: +108.51%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $61.41
Upside: +66.10%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $92.59
Upside: +45.80%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $2.63
Upside: +356.27%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $76.01
Upside: +44.72%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $82.92
Upside: +13.36%
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $7.29
Upside: +791.63%
May 9, 2024
Maintains: Outperform
Price Target: $5 → $5.5
Current: $16.50
Upside: -66.67%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $11.09
Upside: +8.21%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $67.43
Upside: +29.02%
Sep 19, 2023
Reiterates: Outperform
Price Target: $105
Current: $4.35
Upside: +2,313.79%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $329.01
Upside: -12.46%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $122.07
Upside: -13.98%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $26.68
Upside: +462.22%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $64.34
Upside: +32.11%